REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy

Important Disclosures:

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Key Takeaways

• REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after asymptomatic spinal MRI findings were identified in five participants in the CAMPSIITE study.
• The company is evaluating additional imaging and long-term follow-up data with partner NS Pharma to determine the findings' clinical significance and next steps for RGX-121.
• REGENXBIO's other late-stage programs remain on track, including a planned BLA submission for its Duchenne muscular dystrophy gene therapy candidate RGX-202 and fourth-quarter 2026 pivotal data for surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD.
• The Hunter Syndrome treatment market is projected to grow, while REGENXBIO continues to develop one-time gene therapies for rare and retinal diseases.

Hunter Syndrome Program Under Further Review

On August 24, 2026, REGENXBIO Inc. (RGNX:NASDAQ) gave an update on RGX-121 (clemidsogene lanparvovec), its investigational gene therapy intended to treat Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. Hunter Syndrome is a rare, X-linked recessive disease that is caused by a deficiency in the lysosomal enzyme I2S that leads to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS), in tissues. This accumulation results in cell, tissue, and organ dysfunction. Hunter Syndrome is diagnosed in around 2,000 patients globally, with over 500 babies born with the disease every year. According to the press release, the majority of MPS II patients have severe forms of the disease, with early developmental milestones potentially being met but developmental delays becoming readily apparent by 18 to 24 months.

In the announcement, REGENXBIO stated that the FDA (The U.S. Food and Drug Administration) has placed a clinical hold on RGX-121 after the discovery of asymptomatic spinal MRI findings in five participants in its CAMPSIITE study.

"We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121," said Curran Simpson, President and CEO of REGENXBIO. "We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter."

Because spine MRI is not normally conducted for MPS II in clinical practice or trials, the underlying prevalence and clinical significance of these types of asymptomatic findings in this patient population is unknown. Investigators plan to continue observing these patients with periodic imaging only.

"Boys with neuronopathic MPS II experience a multitude of neurodevelopmental and systemic effects. While imaging natural history is limited for this ultra-rare disease, I believe that asymptomatic, likely benign findings like these may be inherent to the impact of Hunter Syndrome throughout the body," said Roberto Giugliani, MD, Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil. "I am pleased that these patients are doing well and remain asymptomatic."

The company and its partner, NS Pharma, are evaluating additional patient imaging and longer-term follow-up data. FDA feedback will be incorporated, including the full clinical hold letter once received, into the next steps for RGX-121.

REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term, even though it has received Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration, and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.

A biopharma company, REGENXBIO, is focused on advancing a late-stage pipeline of one-time treatments for rare and retinal diseases using gene therapy.

Rare Disease Market Continues to Grow

According to Grandview Research, "The global hunter syndrome treatment market size was valued at US$1.3 billion in 2024 and is projected to grow from US$1.5 billion in 2026 to USD 1.8 billion by 2030, at a CAGR of 5.3% from 2025 to 2030." In 2024, the North American market showed the most demand, with a revenue share of 37.5%, due to increasing awareness of the disease and more readily available treatments.

In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Views and Valuations

On August 25, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? wrote about the company, saying: "Biotech is full of surprises and a big movement. RGNX was down big this week due to one of the other pipeline drug candidates [being] put on clinical hold. Unlikely it has any impact on their key catalysts, which is the DMD program that is pending FDA approval. I had discussions with other hedge funds who follow this closely, [and] the worst case is the FDA delaying the current approval by a few months out of extraordinary precautions. The shares are down below the last financing price of US$9; I added a few shares to lower my cost."

As for analyst coverage, Marketbeat lists recent analyst ratings as:

• On August 25, 2026, Yi Chen of H.C. Wainwright reiterated a "Buy" rating but lowered the price target from US$23 to US$21.
• On August 25, 2026, Brian Skorney of Robert W. Baird reiterated a "Buy" rating but lowered the price target from US$32 to US$29.
• On August 7, 2026, Gena Wang of Barclays downgraded the rating from "Overweight" to "Hold".

Duchenne and Wet AMD Programs Offer Near-Term Catalysts

REGENXBIO's investor presentation lists upcoming catalysts for several investigational drugs, including:

• The initiation of a BLA submission for RGX-202, its Duchenne muscular dystrophy gene therapy candidate, in Q3 2026. The company hopes to initiate ex-US RCT in the first half of 2027 and looks forward to potential FDA approval in the second half of 2027.
• The receipt of topline pivotal data for its wet AMD gene therapy candidate, surabgene lomparvovec (sura-vec, ABBV-RGX-314), in Q4 2026 and global regulatory submissions planned for 2027.

Ownership & Share Information¹

REGENXBIO Inc. has a market cap of US$618.54 million, with 66.01 million shares outstanding. The company's 52-week range is US$5.46-US$16.19. Institutions own 65.40% of shares, while Strategic Investors own 0.41%. Management & Insiders own 5.97%, and the remaining 28.22% of shares are held by Retail.

Frequently Asked Questions

Q: What is Hunter Syndrome?
A: Hunter Syndrome, also known as MPS II, is a rare inherited disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S). The deficiency causes certain complex sugars to accumulate in tissues and organs.

Q: What is RGX-121?
A: RGX-121, also known as clemidsogene lanparvovec, is an investigational gene therapy being developed by REGENXBIO to treat Hunter Syndrome.

Q: What is a clinical hold?
A: A clinical hold is an FDA action that pauses some or all clinical investigation of an experimental drug while safety or other regulatory concerns are evaluated.

Q: What is a BLA?
A: A Biologics License Application, or BLA, is a submission to the FDA requesting approval to market a biological product, including certain gene therapies.

Q: What is gene therapy?
A: Gene therapy is an approach that seeks to treat or potentially prevent disease by modifying, replacing, adding, or regulating genetic material within a patient's cells.

Q: What is an orphan drug designation?
A: The FDA's Orphan Drug Designation is intended for drugs developed to treat rare diseases or conditions. The designation can provide certain development incentives and potential regulatory benefits.

Q: What is MPS II?
A: MPS II, or mucopolysaccharidosis type II, is the medical name for Hunter Syndrome. It is an X-linked genetic disorder that can cause progressive effects across multiple organs and tissues.

Q: What are glycosaminoglycans?
A: Glycosaminoglycans, or GAGs, are complex sugar molecules found throughout the body. In Hunter Syndrome, the body cannot properly break down certain GAGs, causing them to accumulate.